Publication Full Title: Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial
Journal: Blood
Published: 12 March 2026
Publication Link: https://ashpublications.org/blood/article/147/11/1168/557305/Orca-T-vs-allogeneic-hematopoietic-stem-cell
Comment by:
Rachele De Domenico, Hematology resident at University of Brescia and ASST Spedali Civili di Brescia, Italy, currently fellow at Institut Català d'Oncologia, Barcelona, Spain
Alberto Mussetti, Director Hematopoietic Cell Transplant/Cell Therapy Unit - Institut Català d’Oncologia - Campus Salut Bellvitge Comprehensive Cancer Center, Barcelona, Spain
Summary
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative strategy for hematological malignancies, driven by the graft-versus-tumor (GVT) effect mediated by donor T cells. However, donor T-cell alloreactivity also instigates graft-versus-host disease (GVHD), which remains the leading cause of non-relapse mortality (NRM) after allo-HCT [1].
Orca-T is a precision-engineered cellular graft designed to address this issue [2].
The Precision-T trial is a multicenter, randomized, phase 3 study evaluating adults with acute leukemia or myelodysplastic syndrome (MDS) undergoing myeloablative allo-HCT from HLA-matched donors. Patients were randomized to receive either Orca-T with single-agent tacrolimus or a conventional, unmanipulated peripheral blood graft with standard tacrolimus and methotrexate (Tac/MTX) as GVHD prophylaxis [2].
At a median follow-up of nearly 1 year, Orca-T met its primary endpoint, demonstrating a significantly superior chronic GVHD-free survival (cGFS) compared to the control arm (78.0% vs. 38.4%; P < .001). Notably, NRM was lower in the Orca-T cohort (3.4% vs. 13.2%; P = .03). Orca-T also reduced the incidence of moderate-to-severe chronic GVHD, serious infections, and immunosuppression-related adverse events, while ensuring robust engraftment and immune reconstitution. No significant differences were observed between the two arms regarding relapse rates, disease-free survival (DFS), or overall survival (OS) [2].
Comment
The pivotal role of donor T cells in graft-versus-host disease (GVHD) was established through pioneering experimental studies in murine models in the late 1970s and early 1980s [3, 4].
Strategies to control donor T-cell alloreactivity have evolved from broad ex vivo T-cell depletion [5]., through pharmacological in vivo modulation with antithymocyte globulin (ATG) [6] and post-transplant cyclophosphamide (PTCy) [7], toward increasingly precise graft engineering based on the rational selection of donor T-cell subsets [8].
The study by Meyer et al. provides the first clinical evidence that selective T-cell manipulation of the graft can translate into improved transplant outcomes, reducing both GVHD and non-relapse mortality (NRM) compared with conventional allo-HCT.
However, several important considerations should be noted. The median follow-up was less than one year, and therefore the long-term effects of Orca-T on GVHD, relapse, and survival remain to be established. Moreover, enrollment was restricted to HLA-matched transplantation after myeloablative conditioning and to a limited number of conditioning, leaving the efficacy of Orca-T with other commonly used regimens, such as treosulfan-based conditioning, largely unexplored. Furthermore, the conventional transplantation arm used tacrolimus plus methotrexate as the sole GVHD prophylaxis strategy, thus precluding direct comparison with other widely used approaches, particularly ATG- or PTCy-based regimens.
Overall, the study provides initial evidence that precision graft manipulation may enable a more personalized and immunologically precise approach to allo-HCT. Nevertheless, further investigation is needed to determine whether these promising results can be extended to other hematologic and immunologic diseases.
In conclusion, Orca-T represents a major clinical advancement driven by a robust biological rationale. This strategy demonstrates that separating GVT from GVHD may be clinically achievable through accurate donor T-cell selection, granting engraftment and immune reconstitution with minimal risk of graft failure, and reducing the rate of GVHD, ultimately leading to an overall improvement in transplant outcomes.
References
- Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010;10(3):213-221. doi:10.1038/nrc2804
- Meyer EH, Salhotra A, Gandhi AP, et al. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026;147(11):1168-1177. doi:10.1182/blood.2025031313
- Korngold R, Sprent J. Lethal GVHD across minor histocompatibility barriers: nature of the effector cells and role of the H-2 complex. Immunol Rev. 1983; 71:5-29. doi:10.1111/j.1600-065x.1983.tb01066.x
- Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150. doi:10.1038/nm915
- Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186-1193. doi:10.1056/NEJM199810223391702
- Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-2947. doi:10.1182/blood.v98.10.2942
- Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650. doi:10.1016/j.bbmt.2008.03.005
- Bleakley M, Heimfeld S, Jones LA, et al. Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant. 2014;20(5):705-716. doi:10.1016/j.bbmt.2014.01.032